Prostate Cancer

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Episode 3 - Radium-223 for the Treatment of CRPC
December 17, 2013 – 
In addition to cytotoxic chemotherapy, immunotherapy, and oral agents that target the androgen pathway, David Crawford, MD, discusses radium-223 as a therapeutic option for the treatment of castration-resistant prostate cancer.
Episode 2 - Immunotherapy in CRPC
December 17, 2013 – 
David Crawford, MD, and David Quinn, MD, discuss the capabilities of new immunotherapy and hormonal agents for the treatment of castration-resistant prostate cancer, as demonstrated by the results of several key clinical trials.
Episode 1 - CRPC: Recent Advances and Paradigm Shifts in Treatment
November 26, 2013 – 
During the opening segment of this panel discussion about recent advances and pharmacoeconomic considerations in the clinical management of Castration-Resistant Prostate Cancer (CRPC), leading experts briefly discuss the clinical and economic burden of CRPC, and explain how a paradigm shift in treatment is improving the disease's outlook.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.